<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9917931</article-id><article-id pub-id-type="pmcid-ver">PMC9917931.1</article-id><article-id pub-id-type="pmcaid">9917931</article-id><article-id pub-id-type="pmcaiid">9917931</article-id><article-id pub-id-type="pmid">36769594</article-id><article-id pub-id-type="doi">10.3390/jcm12030946</article-id><article-id pub-id-type="publisher-id">jcm-12-00946</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association of Genetic Polymorphisms and Serum Levels of miR-1-3p with Postoperative Mortality following Abdominal Aortic Aneurysm Repair</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="T">Tan</given-names></name><xref rid="af1-jcm-12-00946" ref-type="aff">1</xref><xref rid="af2-jcm-12-00946" ref-type="aff">2</xref><xref rid="fn1-jcm-12-00946" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="B">Bo</given-names></name><xref rid="af3-jcm-12-00946" ref-type="aff">3</xref><xref rid="fn1-jcm-12-00946" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yijun</given-names></name><xref rid="af4-jcm-12-00946" ref-type="aff">4</xref><xref rid="af5-jcm-12-00946" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="J">Jun</given-names></name><xref rid="af1-jcm-12-00946" ref-type="aff">1</xref><xref rid="af2-jcm-12-00946" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="C">Chunyan</given-names></name><xref rid="af1-jcm-12-00946" ref-type="aff">1</xref><xref rid="af2-jcm-12-00946" ref-type="aff">2</xref><xref rid="c1-jcm-12-00946" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="Y">Yuan</given-names></name><xref rid="af4-jcm-12-00946" ref-type="aff">4</xref><xref rid="af5-jcm-12-00946" ref-type="aff">5</xref><xref rid="c1-jcm-12-00946" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Kolvenbach</surname><given-names initials="R">Ralf</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-12-00946"><label>1</label>Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang 110001, China</aff><aff id="af2-jcm-12-00946"><label>2</label>Clinical Medical Research Center of Imaging in Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China</aff><aff id="af3-jcm-12-00946"><label>3</label>Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang 110001, China</aff><aff id="af4-jcm-12-00946"><label>4</label>Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, Shenyang 110001, China</aff><aff id="af5-jcm-12-00946"><label>5</label>Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, The First Hospital of China Medical University, Shenyang 110001, China</aff><author-notes><corresp id="c1-jcm-12-00946"><label>*</label>Correspondence: <email>macy@cmu1h.com</email> (C.M.); <email>yuanyuan@cmu.edu.cn</email> (Y.Y.); Tel.: +86-024-83282126 (C.M.); +86-024-83282153 (Y.Y.)</corresp><fn id="fn1-jcm-12-00946"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>1</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2023</year></pub-date><volume>12</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">428746</issue-id><elocation-id>946</elocation-id><history><date date-type="received"><day>28</day><month>12</month><year>2022</year></date><date date-type="rev-recd"><day>20</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>11</day><month>02</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-04 04:25:38.203"><day>04</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-12-00946.pdf"/><abstract><p>Background: Several miRNAs have been implicated in the clinical outcomes of cardiovascular disorders, but the role of miR-1-3p in abdominal aortic aneurysm (AAA) prognosis remains unclear. This study aimed to investigate the correlation of single nucleotide polymorphisms (SNPs) in pri-miR-1-3p and mature miR-1-3p expression with postoperative mortality of AAA patients. Methods: A total of 230 AAA patients who received AAA repair were recruited and followed up for 5 years. SNP genotyping was carried out using KASP method and relative expression of serum miR-1-3p was measured with qRT-PCR. Results: Multivariate Cox regression analyses showed that both rs2155975 and rs4591246 variant genotypes were associated with increased all-cause mortality of postoperative AAA patients after adjusting possible confounders. Patients who died tended to have lower baseline miR-1-3p expression (overall and for age &lt; 65 years, aneurysm-related death or cardiac death subgroup) when compared to alive patients; further Cox regression yielded an independent relationship of preoperative low serum miR-1-3p levels with incidents of all-cause death. Patients carrying rs2155975 AG + GG or rs4591246 AG + AA genotype had a higher ratio of low miR-1-3p levels in contrast to those with AA or GG genotype, respectively. The Kaplan&#8211;Meier survival curves suggested that the combined genotype in rs2155975 or rs4591246 and low miR-1-3p levels could decrease the overall survival of AAA patients during 5-year follow-up. Conclusions: This pilot study demonstrated the importance of rs2155975 and rs4591246 polymorphisms and baseline serum miR-1-3p levels as promising markers to predict mortality among patients following AAA repair.</p></abstract><kwd-group><kwd>abdominal aortic aneurysm</kwd><kwd>miRNA</kwd><kwd>polymorphism</kwd><kwd>prognosis</kwd><kwd>mortality</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82001828</award-id></award-group><funding-statement>This work was funded by the National Natural Science Foundation of China (grant number 82001828).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-12-00946"><title>1. Introduction</title><p>Abdominal aortic aneurysm (AAA) is a potentially life-threatening cardiovascular disease typically described as a focal weakening and dilatation of the abdominal aorta [<xref rid="B1-jcm-12-00946" ref-type="bibr">1</xref>]. The major epidemiological risk factors for AAA include male sex, older age, smoking, hypertension and dyslipidemia [<xref rid="B1-jcm-12-00946" ref-type="bibr">1</xref>,<xref rid="B2-jcm-12-00946" ref-type="bibr">2</xref>]. Aortic wall inflammation, vascular smooth muscle cell (VSMC) apoptosis and extracellular matrix degradation are the key pathological hallmarks in the progress of AAA formation [<xref rid="B3-jcm-12-00946" ref-type="bibr">3</xref>,<xref rid="B4-jcm-12-00946" ref-type="bibr">4</xref>]. At present, a patient with large AAA or symptomatic or ruptured AAA of any size should be referred for AAA repair by either open aneurysm repair (OAR) or endovascular aneurysm repair (EVAR) [<xref rid="B5-jcm-12-00946" ref-type="bibr">5</xref>,<xref rid="B6-jcm-12-00946" ref-type="bibr">6</xref>]. Despite an early benefit being realized with EVAR, no difference was observed in all-cause mortality between the two procedures in the mid- or longer-term follow-up for AAA patients [<xref rid="B7-jcm-12-00946" ref-type="bibr">7</xref>,<xref rid="B8-jcm-12-00946" ref-type="bibr">8</xref>,<xref rid="B9-jcm-12-00946" ref-type="bibr">9</xref>]. Notably, a genetic component plays a crucial role in predicting the risk of AAA occurrence and adverse outcomes after therapy [<xref rid="B10-jcm-12-00946" ref-type="bibr">10</xref>]. Although clinical detection methods and treatment strategies have been improved, elderly patients still suffer from major postoperative complications and poor quality of life, and the 5-year survival rate for AAA patients remains low [<xref rid="B11-jcm-12-00946" ref-type="bibr">11</xref>,<xref rid="B12-jcm-12-00946" ref-type="bibr">12</xref>]. There is an urgent need to identify preoperative determinants of future mortality in AAA patients, which may optimize risk stratification and improve clinical decision-making and management.</p><p>As a major type of genetic variant, a series of single nucleotide polymorphisms (SNPs) have been considered candidate biomarkers of genetic background to predict risk, progression and prognosis of diseases [<xref rid="B13-jcm-12-00946" ref-type="bibr">13</xref>]. MicroRNAs (miRNAs) are small non-protein coding single-stranded RNAs that are derived from long primary miRNAs (pri-miRNAs) and exert the main function of post-transcriptional gene regulation [<xref rid="B14-jcm-12-00946" ref-type="bibr">14</xref>,<xref rid="B15-jcm-12-00946" ref-type="bibr">15</xref>]. Variants in non-coding regions account for more than one-third of the variants identified by genome-wide association studies [<xref rid="B16-jcm-12-00946" ref-type="bibr">16</xref>]. The presence of SNP in miRNA genes may have an influence on its transcription, maturation and miRNA-mRNA interaction, and explain the aberrant miRNA expression in multiple diseases [<xref rid="B17-jcm-12-00946" ref-type="bibr">17</xref>,<xref rid="B18-jcm-12-00946" ref-type="bibr">18</xref>]. It has become evident that functional miRNA polymorphisms may confer genetic susceptibility to certain diseases and be related to the clinical outcomes of patients with these disorders [<xref rid="B19-jcm-12-00946" ref-type="bibr">19</xref>,<xref rid="B20-jcm-12-00946" ref-type="bibr">20</xref>,<xref rid="B21-jcm-12-00946" ref-type="bibr">21</xref>]. However, reports assigning SNPs in miRNA to human AAA prognosis are still lacking.</p><p>Recently, miR-1-3p has been shown to be a promising and effective biomarker implicated in the pathogenesis of cardiovascular events [<xref rid="B22-jcm-12-00946" ref-type="bibr">22</xref>,<xref rid="B23-jcm-12-00946" ref-type="bibr">23</xref>]. MiR-1-3p was downregulated and correlated with cardiac function in human hypertrophic cardiomyopathy [<xref rid="B24-jcm-12-00946" ref-type="bibr">24</xref>]. In VSMCs, miR-1 has been reported to be an important modulator of gene expression and cell contractility, and acts a critical role in regulating pulmonary vascular remodeling of pulmonary arterial hypertension patients [<xref rid="B25-jcm-12-00946" ref-type="bibr">25</xref>,<xref rid="B26-jcm-12-00946" ref-type="bibr">26</xref>]. Although accumulating evidence suggests that changes in the expression of several circulating miRNAs are linked with the adverse outcomes of AAA patients [<xref rid="B27-jcm-12-00946" ref-type="bibr">27</xref>,<xref rid="B28-jcm-12-00946" ref-type="bibr">28</xref>], the effect of serum miR-1-3p expression on the prognosis of patients receiving AAA surgery has not been reported.</p><p>In this prospective study, we sought to further evaluate whether the pri-miR-1-3p polymorphisms along with serum miR-1-3p expression predicted all-cause mortality in patients undergoing AAA repair, based on a Chinese population. These data may aid in the timing of clinical surgical intervention, counseling of patients on expected outcomes, and improving late survival.</p></sec><sec id="sec2-jcm-12-00946"><title>2. Materials and Methods</title><sec id="sec2dot1-jcm-12-00946"><title>2.1. Study Population</title><p>We enrolled a total of 230 AAA patients who underwent a successful EVAR or OAR procedure in the First Hospital of China Medical University and were successfully followed up for 5 years. Preoperative computed tomography angiography was applied to diagnose the patients and assess the maximum AAA diameter. Exclusion criteria included the subjects with traumatic AAA, previous aortic surgery, congenital disorder, malignant tumor, infectious disease, hematological disease, severe hepatic or renal dysfunction (end-stage renal disease requiring dialysis treatment) or severe heart disease (congestive heart failure, hypertrophic obstructive cardiomyopathy, severe valvular stenosis or regurgitation and/or life-threatening arrhythmias). Patients who had no follow-up information or died within 30 days after surgery were also excluded. Blood clots and serum samples were collected from AAA patients before surgery. Baseline demographic data, comorbidities and surgical information were obtained from the medical records. The study was approved by the Ethics Committee of the First Hospital of China Medical University (Shenyang, China). Informed consent was obtained from each participant.</p><p>The median follow-up time was 5 years and the primary outcome of interest was all-cause mortality within 5 years after AAA surgery. The overall survival was measured as the period from the time of surgical treatment to the date of death from any cause or the last follow-up. Patients were followed up for a maximum of 5 years via annual telephone contact or clinical visits, and the most recent follow-up assessments were completed on 17 February 2022.</p></sec><sec id="sec2dot2-jcm-12-00946"><title>2.2. SNP Selection</title><p>We utilized the NCBI dbSNP database and Haploview software 4.2 to select tagger SNPs in pri-miR-1-3p. The selection criteria were: (1) minor allele frequency (MAF) &gt; 0.05 in the Chinese Han population (CHB); (2) lack of linkage disequilibrium (<italic toggle="yes">r<sup>2</sup></italic> &lt; 0.8) between tagger SNPs; and (3) following the Hardy&#8211;Weinberg equilibrium (HWE, <italic toggle="yes">p</italic> &gt; 0.05). Consequently, three tagger SNPs were selected as research targets, including rs2155975, rs4591246 and rs9989532. Based upon the SNPinfo website, it is predicted that these tagger SNPs may affect the activity of transcription factor binding sites.</p></sec><sec id="sec2dot3-jcm-12-00946"><title>2.3. DNA Extraction and Genotyping</title><p>Genomic DNA was extracted from blood clots using a standard phenol-chloroform method. The concentration and quality of DNA were checked with NanoDrop 2000 (Thermo Fisher Scientific, Waltham, USA). SNP genotyping was performed by Baygene Biotechnology Company Limited (Shanghai, China) with the KASP method using SNPLine platform (LGC, United Kingdom). Additionally, 10% of the DNA samples were randomly selected for duplicate genotyping, and the results showed 100% concordance.</p></sec><sec id="sec2dot4-jcm-12-00946"><title>2.4. Quantitative Real-Time PCR (qRT-PCR)</title><p>Total RNA was isolated from serum with Trizol reagent (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer&#8217;s protocol. We used the miRcute miRNA First-Strand cDNA Synthesis Kit (Tiangen, Beijing, China) and miRcute miRNA SYBR Green qPCR Detection Kit (Tiangen, Beijing, China) for reverse transcription and quantitative detection, respectively. The primer sequences for qRT-PCR were as follows: miR-1-3p, forward 5&#8242;-TGGAATGTAAAGAAGTATGTAT-3&#8242; and reverse 5&#8242;-CGCTTCACGAATTTGCGTG-3&#8242;; U6, forward 5&#8242;-CTCGCTTCGGCAGCACA-3&#8242; and reverse 5&#8242;-AACGCTTCACGAATTTGCGT-3&#8242;. The qRT-PCR was performed under the following conditions: 95 &#176;C for 15 min, followed by 40 cycles of 94 &#176;C for 20 s and 60 &#176;C for 34 s. U6 was adopted as the internal control and the relative expression of miR-1-3p was determined with the 2<sup>&#8722;&#916;&#916;CT</sup> method.</p></sec><sec id="sec2dot5-jcm-12-00946"><title>2.5. Statistical Analysis</title><p>All statistical analyses were performed with SPSS 23.0 software. Continuous data were described as mean &#177; standard deviation (SD), and categorical data were presented as counts and percentages. Normally distributed data were analyzed by Student&#8217;s <italic toggle="yes">t</italic>-test, nonparametric data were compared by Mann&#8211;Whitney U-test and categorical data were tested with Chi-square test. A receiver operating characteristic (ROC) curve was employed to determine a cut-off value of serum miR-1-3p levels associated with 5-year mortality. The overall survival was analyzed with the Kaplan&#8211;Meier method and differences were compared with log-rank test. The effects of SNPs and miR-1-3p expression on all-cause mortality were evaluated using univariate and multivariate Cox regression models by calculating hazard ratios (HRs) and their 95% confidence intervals (95% CIs). A two-tailed <italic toggle="yes">p</italic> value &lt; 0.05 was deemed statistically significant. Additionally, the dominant and recessive models were separately defined as heterozygote + homozygote variant vs. homozygote wild and homozygote variant vs. heterozygote + homozygote wild.</p></sec></sec><sec sec-type="results" id="sec3-jcm-12-00946"><title>3. Results</title><sec id="sec3dot1-jcm-12-00946"><title>3.1. Baseline Characteristics of the Study Population</title><p>Detailed demographic and clinical characteristics of the total enrolled population are listed in <xref rid="jcm-12-00946-t001" ref-type="table">Table 1</xref>. Overall, 57 patients (24.8%) died during the follow-up period of 5 years consisting of 11 aneurysm-related deaths and 9 cardiac death events. Patients who died were older or had larger AAA diameters or a higher ratio of renal insufficiency compared with those who survived (all <italic toggle="yes">p</italic> &lt; 0.05). Then, the prognostic impact of clinical features on mortality was evaluated by univariate Cox regression analysis and only variables that achieved <italic toggle="yes">p</italic> &lt; 0.10 were included in the subsequent multivariate Cox regression models (<xref rid="app1-jcm-12-00946" ref-type="app">Table S1</xref>).</p></sec><sec id="sec3dot2-jcm-12-00946"><title>3.2. Association of the Studied SNPs with AAA Prognosis</title><p>Based on all enrolled AAA patients, the relationship of rs2155975, rs4591246 and rs9989532 polymorphisms with postoperative all-cause mortality was estimated in univariate and multivariate analyses. Compared to homozygous wild-type genotype, the heterozygous genotype, homozygous variant genotype and dominant model of either rs2155975 or rs4591246 could significantly increase the risk of all-cause death in multivariate Cox analysis with adjustment for age, renal insufficiency, maximum AAA diameter, presence of surgical complications and presence of postoperative renal dysfunction (for rs2155975, AG vs. AA: <italic toggle="yes">p</italic> = 0.004, HR = 3.591, 95% CI = 1.489-8.658, GG vs. AA: <italic toggle="yes">p</italic> = 0.010, HR = 3.590, 95% CI = 1.358-9.487, dominant model: <italic toggle="yes">p</italic> = 0.003, HR = 3.668, 95% CI = 1.560-8.627; for rs4591246, AG vs. GG: <italic toggle="yes">p</italic> = 0.016, HR = 2.117, 95% CI = 1.150-3.898, AA vs. GG: <italic toggle="yes">p</italic> = 0.039, HR = 2.737, 95% CI = 1.043-5.400, dominant model: <italic toggle="yes">p</italic> = 0.007, HR = 2.225, 95% CI = 1.240-3.992) (<xref rid="jcm-12-00946-t002" ref-type="table">Table 2</xref>). Moreover, Cox regression models showed no statistical association between rs9989532 polymorphism and AAA prognosis. The Kaplan&#8211;Meier survival curves indicated that the dominant model in rs2155975 and rs4591246 could significantly decrease the overall survival of AAA patients in contrast to homozygous wild-type genotype (all <italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="jcm-12-00946-f001" ref-type="fig">Figure 1</xref>A,B).</p></sec><sec id="sec3dot3-jcm-12-00946"><title>3.3. Association of Serum miR-1-3p Expression with AAA Prognosis</title><p>A total of 145 serum samples with SNP genotyping information were available for miR-1-3p detection. In the overall comparison, patients who died due to all causes were more likely to have lower preoperative miR-1-3p levels than those who survived (0.89 &#177; 0.60 vs. 1.27 &#177; 0.92, <italic toggle="yes">p</italic> = 0.011) (<xref rid="jcm-12-00946-t003" ref-type="table">Table 3</xref>). The stratified analyses showed that baseline miR-1-3p expression was significantly lower in dead patients when compared with alive subjects in age &lt; 65 years, aneurysm-related death and cardiac death subgroups (all <italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="jcm-12-00946-t003" ref-type="table">Table 3</xref>). Meanwhile, Cox regression analyses suggested that increased miR-1-3p expression was correlated with a reduced risk of all-cause death even after adjusting for age, renal insufficiency, maximum AAA diameter, presence of surgical complications and presence of postoperative renal dysfunction (<italic toggle="yes">p</italic> = 0.030, HR = 0.496 per unit increase, 95% CI = 0.264&#8211;0.933). In addition, an ideal cut-off value of miR-1-3p levels determined by the ROC curve against mortality was 1.03 with the area under the curve of 0.643 (<italic toggle="yes">p</italic> = 0.012, 95% CI = 0.541&#8211;0.746). Using this cut-off value, we differentiated patients into low level (&lt;1.03) group and high level (&#8805;1.03) group. With respect to this classification, preoperative low levels of serum miR-1-3p were found to be significantly associated with increased all-cause mortality of AAA patients in both univariate and multivariate Cox models (all <italic toggle="yes">p</italic> &lt; 0.05) (<xref rid="jcm-12-00946-t004" ref-type="table">Table 4</xref>). The corresponding survival curve revealed that patients with low miR-1-3p levels had a worse overall survival when compared to those with high miR-1-3p levels (<italic toggle="yes">p</italic> = 0.001) (<xref rid="jcm-12-00946-f001" ref-type="fig">Figure 1</xref>C).</p></sec><sec id="sec3dot4-jcm-12-00946"><title>3.4. Effects of rs2155975 and rs4591246 on the Expression of Serum miR-1-3p</title><p>To explore the influence of two significant polymorphisms on gene expression, we assessed the serum levels of miR-1-3p in patients carrying different genotypes of rs2155975 or rs4591246. Patients with AG + GG genotype of rs2155975 exhibited a much higher proportion of low miR-1-3p levels than those with AA genotype (<italic toggle="yes">p</italic> = 0.029) (<xref rid="jcm-12-00946-t005" ref-type="table">Table 5</xref>). Similarly, in the case of rs4591246, carriers with AG + AA genotype displayed an elevated ratio of low miR-1-3p levels in comparison to those with GG genotype (<italic toggle="yes">p</italic> = 0.029) (<xref rid="jcm-12-00946-t005" ref-type="table">Table 5</xref>). However, when miR-1-3p expression was taken as a continuous variable, rs2155975 and rs4591246 had no statistical impact on serum miR-1-3p levels in AAA patients (<xref rid="jcm-12-00946-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-12-00946"><title>4. Discussion</title><p>With the support of molecular biomarkers, precision medicine has advanced prognostic prediction. Here, we present the results of a 5-year prospective study that elucidates the influence of SNPs in pri-miR-1-3p as well as serum miR-1-3p expression on AAA prognosis, with a specific focus on all-cause mortality under surgical therapy. Our findings provide a novel clinical tool to assess the risk of subsequent death events after AAA repair, which may help guide the management of AAA patients.</p><p>The long-term mortality results for AAA patients after surgery with follow-up ranging from 3 to 15 years have been reported, and the data taken together exhibit a trend of approximately 5% all-cause mortality with each year of postoperative follow-up [<xref rid="B29-jcm-12-00946" ref-type="bibr">29</xref>,<xref rid="B30-jcm-12-00946" ref-type="bibr">30</xref>]. Our study presented an overall mortality rate of 24.8% at a maximum follow-up of 5 years, which was in line with the above trend. It has been demonstrated that SNPs located in pri-miRNAs may interfere with the processing of miRNAs and affect mature miRNA expression as a consequence, which leads to altered biological functions and thereby influences the survival outcome of patients [<xref rid="B31-jcm-12-00946" ref-type="bibr">31</xref>,<xref rid="B32-jcm-12-00946" ref-type="bibr">32</xref>,<xref rid="B33-jcm-12-00946" ref-type="bibr">33</xref>]. The predictive utility of pri-miRNA SNPs for overall survival has been studied in several types of human disease [<xref rid="B20-jcm-12-00946" ref-type="bibr">20</xref>,<xref rid="B21-jcm-12-00946" ref-type="bibr">21</xref>,<xref rid="B33-jcm-12-00946" ref-type="bibr">33</xref>]. In our study, Cox regression models revealed that heterozygous genotype and dominant model of both rs2155975 and rs4591246 could increase 5-year all-cause mortality of AAA patients after surgical intervention even controlling for possible confounding factors. Further survival analysis demonstrated that the combined variant genotype of either rs2155975 or rs4591246 was closely related to worse overall survival in comparison with homozygous wild-type genotype. To some extent, these data might provide a clue for analyzing the prognostic value of rs2155975 and rs4591246 in predicting the mortality after AAA repair. However, the mechanisms underlying how they are involved in postoperative AAA mortality are complicated and need more in-depth research to reveal them.</p><p>In fact, a number of miRNAs have been identified as serum biomarkers with high potential to be used in clinical diagnosis in a stable form, or provide accurate prognosis for survival in patients with cardiovascular disorders [<xref rid="B14-jcm-12-00946" ref-type="bibr">14</xref>,<xref rid="B34-jcm-12-00946" ref-type="bibr">34</xref>]. Inflammation plays a central role in AAA pathogenesis, and a growing body of studies has noted that AAA patients with elevated levels of systemic inflammatory markers before surgery tended to have more frequent postoperative complications and major adverse events, including all-cause death [<xref rid="B35-jcm-12-00946" ref-type="bibr">35</xref>,<xref rid="B36-jcm-12-00946" ref-type="bibr">36</xref>,<xref rid="B37-jcm-12-00946" ref-type="bibr">37</xref>]. As a muscle-specific miRNA, miR-1-3p has been discovered to participate in modulating inflammatory responses in a variety of biological processes and pathologies [<xref rid="B38-jcm-12-00946" ref-type="bibr">38</xref>,<xref rid="B39-jcm-12-00946" ref-type="bibr">39</xref>,<xref rid="B40-jcm-12-00946" ref-type="bibr">40</xref>]. Badacz et al. revealed that circulating miR-1-3p appeared as a prognostic factor of secondary cardiovascular events during follow-up [<xref rid="B23-jcm-12-00946" ref-type="bibr">23</xref>]. Navickas et al. suggested that miR-1 could regulate the endothelial function and angiogenesis, apoptosis as well as cardiac myocyte differentiation, and its circulating abundance was markedly correlated with worse myocardial infarction outcome [<xref rid="B34-jcm-12-00946" ref-type="bibr">34</xref>]. In the current study, it was interesting to note that AAA patients who died due to all-cause, aneurysm-related or cardiac events at the follow-up exhibited lower preoperative levels of serum miR-1-3p compared with subjects who survived. In addition, we observed that reduced miR-1-3p expression was a strong predictor of 5-year all-cause mortality risk of patients after AAA repair, independent of potential confounders. The survival curve indicated that AAA patients with low levels of serum miR-1-3p versus high levels were more likely to have shorter overall survival. Therefore, determining serum miR-1-3p at baseline could be useful in implementing measures to improve their clinical outcomes.</p><p>Furthermore, we determined that the presence of genetic variation in pri-miR-1-3p had a remarkable effect on the production of mature miR-1-3p. In detail, AAA patients with rs2155975 AG + GG or rs4591246 AG + AA genotype displayed a much higher proportion of low miR-1-3p levels in serum than carriers of the homozygous wild-type genotype. According to SNPinfo database, rs2155975 and rs4591246 were putatively located in the transcription factor binding sites of pri-miR-1-3p, where they might regulate the binding activity and impact the expression of mature miR-1-3p. Taken together, it is reasonable to suppose that rs2155975 and rs4591246 may be functional SNPs and contribute to the long-term mortality of AAA patients after surgery via modifying miR-1-3p expression levels. In the same way, some miRNA SNPs have been recognized to affect disease prognosis through regulating the expression of mature miRNAs [<xref rid="B21-jcm-12-00946" ref-type="bibr">21</xref>,<xref rid="B41-jcm-12-00946" ref-type="bibr">41</xref>,<xref rid="B42-jcm-12-00946" ref-type="bibr">42</xref>].</p><p>Some limitations should be acknowledged. First, we included tagger SNPs located in pri-miR-1-3p and more SNPs in multiple miRNAs needed to be detected. Second, despite of our efforts to collect necessary data, certain variables that might affect patients&#8217; survival after surgery were unavailable. Third, this research was based upon a single institution and the number of samples was relatively small, which limited the evaluation of cause-specific mortality such as aneurysm-related death and cardiac death. Therefore, our results should be confirmed in a multicenter study with a larger sample size and longer follow-up.</p></sec><sec sec-type="conclusions" id="sec5-jcm-12-00946"><title>5. Conclusions</title><p>In summary, this study discovered that miR-1-3p polymorphisms and low expression were closely linked to increased 5-year all-cause mortality and shorter survival of patients undergoing AAA repair. The combined variant genotype of either rs2155975 or rs4591246 could affect the expression of serum miR-1-3p. Thus, SNP rs2155975 and rs4591246 and miR-1-3p expression might be used as prognostic indicators to predict postoperative death events among AAA patients, which could be helpful in the preoperative counselling and decision-making process.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-jcm-12-00946"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/jcm12030946/s1">https://www.mdpi.com/article/10.3390/jcm12030946/s1</uri>, Table S1: Univariate Cox regression analysis for the prognostic impact of clinical features on all-cause mortality after AAA repair.</p><supplementary-material id="jcm-12-00946-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jcm-12-00946-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>T.L., C.M. and Y.Y. designed the study. T.L. analyzed data and wrote the manuscript. B.J. and Y.W. performed the experiments and collected data. B.J. and J.Y. contributed reagents and materials. C.M. and Y.Y. interpreted the results. T.L., B.J. and Y.Y. participated in revising the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was approved by the Ethics Committee of the First Hospital of China Medical University (Shenyang, China) (approval code: 2020-146-2; approval date: 7 April 2020), and conducted according to the guidelines of the Declaration of Helsinki of 1975 and its further revisions.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AAA</td><td align="left" valign="middle" rowspan="1" colspan="1">abdominal aortic aneurysm</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHB</td><td align="left" valign="middle" rowspan="1" colspan="1">Chinese Han population</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CI</td><td align="left" valign="middle" rowspan="1" colspan="1">confidence interval</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EVAR</td><td align="left" valign="middle" rowspan="1" colspan="1">endovascular aneurysm repair</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HR</td><td align="left" valign="middle" rowspan="1" colspan="1">hazard ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HWE</td><td align="left" valign="middle" rowspan="1" colspan="1">Hardy&#8211;Weinberg equilibrium</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAF</td><td align="left" valign="middle" rowspan="1" colspan="1">minor allele frequency</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">miRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">microRNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OAR</td><td align="left" valign="middle" rowspan="1" colspan="1">open aneurysm repair</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">pri-miRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">primary miRNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROC</td><td align="left" valign="middle" rowspan="1" colspan="1">receiver operating characteristic</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SD</td><td align="left" valign="middle" rowspan="1" colspan="1">standard deviation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNP</td><td align="left" valign="middle" rowspan="1" colspan="1">single nucleotide polymorphism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VSMC</td><td align="left" valign="middle" rowspan="1" colspan="1">vascular smooth muscle cell</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-jcm-12-00946"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anagnostakos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>B.K.</given-names></name></person-group><article-title>Abdominal aortic aneurysms</article-title><source>Prog. Cardiovasc. Dis.</source><year>2021</year><volume>65</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2021.03.009</pub-id><pub-id pub-id-type="pmid">33831398</pub-id></element-citation></ref><ref id="B2-jcm-12-00946"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Golledge</surname><given-names>J.</given-names></name></person-group><article-title>Risk factors and mouse models of abdominal aortic aneurysm rupture</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>7250</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21197250</pub-id><pub-id pub-id-type="pmid">33008131</pub-id><pub-id pub-id-type="pmcid">PMC7583758</pub-id></element-citation></ref><ref id="B3-jcm-12-00946"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Loftin</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>C.G.</given-names></name></person-group><article-title>Development of pharmacotherapies for abdominal aortic aneurysms</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>153</volume><fpage>113340</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113340</pub-id><pub-id pub-id-type="pmid">35780618</pub-id><pub-id pub-id-type="pmcid">PMC9514980</pub-id></element-citation></ref><ref id="B4-jcm-12-00946"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jauhiainen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kiema</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hedman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laakkonen</surname><given-names>J.P.</given-names></name></person-group><article-title>Large vessel cell heterogeneity and plasticity: Focus in aortic aneurysms</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2022</year><volume>42</volume><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.121.316237</pub-id><pub-id pub-id-type="pmid">35587695</pub-id></element-citation></ref><ref id="B5-jcm-12-00946"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isselbacher</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Preventza</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hamilton Black</surname><given-names>J.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Augoustides</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Bolen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Braverman</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Brown-Zimmerman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.P.</given-names></name><etal/></person-group><article-title>2022 acc/aha guideline for the diagnosis and management of aortic disease: A report of the american heart association/american college of cardiology joint committee on clinical practice guidelines</article-title><source>Circulation</source><year>2022</year><volume>146</volume><fpage>e334</fpage><lpage>e482</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001106</pub-id><pub-id pub-id-type="pmid">36322642</pub-id><pub-id pub-id-type="pmcid">PMC9876736</pub-id></element-citation></ref><ref id="B6-jcm-12-00946"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golledge</surname><given-names>J.</given-names></name></person-group><article-title>Abdominal aortic aneurysm: Update on pathogenesis and medical treatments</article-title><source>Nat. Rev. Cardiol.</source><year>2019</year><volume>16</volume><fpage>225</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0114-9</pub-id><pub-id pub-id-type="pmid">30443031</pub-id></element-citation></ref><ref id="B7-jcm-12-00946"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Parina</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.E.</given-names></name></person-group><article-title>Survival after endovascular vs. open aortic aneurysm repairs</article-title><source>JAMA Surg.</source><year>2015</year><volume>150</volume><fpage>1160</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2015.2644</pub-id><pub-id pub-id-type="pmid">26331571</pub-id></element-citation></ref><ref id="B8-jcm-12-00946"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kainth</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Sura</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Wittgen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zakhary</surname><given-names>E.</given-names></name><name name-style="western"><surname>Smeds</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Participants</surname><given-names>G.</given-names></name></person-group><article-title>Outcomes after endovascular reintervention for aortic interventions</article-title><source>J. Vasc. Surg.</source><year>2022</year><volume>75</volume><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2021.08.090</pub-id><pub-id pub-id-type="pmid">34592379</pub-id></element-citation></ref><ref id="B9-jcm-12-00946"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokoyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>H.</given-names></name></person-group><article-title>Meta-analysis of phase-specific survival after elective endovascular versus surgical repair of abdominal aortic aneurysm from randomized controlled trials and propensity score-matched studies</article-title><source>J. Vasc. Surg.</source><year>2020</year><volume>72</volume><fpage>1464</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2020.03.041</pub-id><pub-id pub-id-type="pmid">32330598</pub-id></element-citation></ref><ref id="B10-jcm-12-00946"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurung</surname><given-names>R.</given-names></name><name name-style="western"><surname>Choong</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Foo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sorokin</surname><given-names>V.</given-names></name></person-group><article-title>Genetic and epigenetic mechanisms underlying vascular smooth muscle cell phenotypic modulation in abdominal aortic aneurysm</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>6334</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21176334</pub-id><pub-id pub-id-type="pmid">32878347</pub-id><pub-id pub-id-type="pmcid">PMC7504666</pub-id></element-citation></ref><ref id="B11-jcm-12-00946"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemingway</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>French</surname><given-names>B.</given-names></name><name name-style="western"><surname>Caps</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benyakorn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Quiroga</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Starnes</surname><given-names>B.W.</given-names></name></person-group><article-title>Preoperative risk score accuracy confirmed in a modern ruptured abdominal aortic aneurysm experience</article-title><source>J. Vasc. Surg.</source><year>2021</year><volume>74</volume><fpage>1508</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2021.04.043</pub-id><pub-id pub-id-type="pmid">33957228</pub-id></element-citation></ref><ref id="B12-jcm-12-00946"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>D.</given-names></name></person-group><article-title>The impact of frailty on outcomes of elderly patients after major vascular surgery: A systematic review and meta-analysis</article-title><source>Eur. J. Vasc. Endovasc. Surg.</source><year>2018</year><volume>56</volume><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2018.07.012</pub-id><pub-id pub-id-type="pmid">30122332</pub-id></element-citation></ref><ref id="B13-jcm-12-00946"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaker</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ayeldeen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abdelhamid</surname><given-names>A.</given-names></name></person-group><article-title>The impact of single nucleotide polymorphism in the long non-coding meg3 gene on microrna-182 and microrna-29 expression levels in the development of breast cancer in egyptian women</article-title><source>Front. Genet.</source><year>2021</year><volume>12</volume><fpage>683809</fpage><pub-id pub-id-type="doi">10.3389/fgene.2021.683809</pub-id><pub-id pub-id-type="pmid">34421993</pub-id><pub-id pub-id-type="pmcid">PMC8371747</pub-id></element-citation></ref><ref id="B14-jcm-12-00946"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirvani Samani</surname><given-names>O.</given-names></name><name name-style="western"><surname>Scherr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kayvanpour</surname><given-names>E.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Gi</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Frese</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Nietsch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fehlmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sandke</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Marathon-induced cardiac strain as model for the evaluation of diagnostic micrornas for acute myocardial infarction</article-title><source>J. Clin. Med.</source><year>2021</year><volume>11</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11010005</pub-id><pub-id pub-id-type="pmid">35011745</pub-id><pub-id pub-id-type="pmcid">PMC8745173</pub-id></element-citation></ref><ref id="B15-jcm-12-00946"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>B.R.</given-names></name></person-group><article-title>Recognition and cleavage of primary microrna precursors by the nuclear processing enzyme drosha</article-title><source>EMBO J.</source><year>2005</year><volume>24</volume><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600491</pub-id><pub-id pub-id-type="pmid">15565168</pub-id><pub-id pub-id-type="pmcid">PMC544904</pub-id></element-citation></ref><ref id="B16-jcm-12-00946"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.Q.</given-names></name></person-group><article-title>Non-coding rna polymorphisms (rs2910164 and rs1333049) associated with prognosis of lung cancer under platinum-based chemotherapy</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><fpage>709528</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.709528</pub-id><pub-id pub-id-type="pmid">34603024</pub-id><pub-id pub-id-type="pmcid">PMC8481925</pub-id></element-citation></ref><ref id="B17-jcm-12-00946"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levkova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mihaylova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Manev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maneva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hadgiev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Conev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Donev</surname><given-names>I.</given-names></name></person-group><article-title>Single nucleotide polymorphisms in microrna genes and colorectal cancer risk and prognosis</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10010156</pub-id><pub-id pub-id-type="pmid">35052835</pub-id><pub-id pub-id-type="pmcid">PMC8773793</pub-id></element-citation></ref><ref id="B18-jcm-12-00946"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Robles</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>C.C.</given-names></name></person-group><article-title>Genetic variation in microrna networks: The implications for cancer research</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>389</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nrc2867</pub-id><pub-id pub-id-type="pmid">20495573</pub-id><pub-id pub-id-type="pmcid">PMC2950312</pub-id></element-citation></ref><ref id="B19-jcm-12-00946"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Z.</given-names></name></person-group><article-title>Association of the microrna-146a snp rs2910164 with ischemic stroke incidence and prognosis in a Chinese population</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>660</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17050660</pub-id><pub-id pub-id-type="pmid">27164084</pub-id><pub-id pub-id-type="pmcid">PMC4881486</pub-id></element-citation></ref><ref id="B20-jcm-12-00946"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>The pri-let-7a-2 rs1143770c&gt;t is associated with prognosis of surgically resected non-small cell lung cancer</article-title><source>Gene</source><year>2016</year><volume>577</volume><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2015.11.036</pub-id><pub-id pub-id-type="pmid">26625972</pub-id></element-citation></ref><ref id="B21-jcm-12-00946"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullany</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Herrick</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Slattery</surname><given-names>M.L.</given-names></name></person-group><article-title>Single nucleotide polymorphisms within micrornas, microrna targets, and microrna biogenesis genes and their impact on colorectal cancer survival</article-title><source>Genes Chromosomes Cancer</source><year>2017</year><volume>56</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1002/gcc.22434</pub-id><pub-id pub-id-type="pmid">27859935</pub-id><pub-id pub-id-type="pmcid">PMC6007859</pub-id></element-citation></ref><ref id="B22-jcm-12-00946"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Sepsis plasma-derived exosomal mir-1-3p induces endothelial cell dysfunction by targeting serp1</article-title><source>Clin. Sci.</source><year>2021</year><volume>135</volume><fpage>347</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1042/CS20200573</pub-id><pub-id pub-id-type="pmid">33416075</pub-id><pub-id pub-id-type="pmcid">PMC7843403</pub-id></element-citation></ref><ref id="B23-jcm-12-00946"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badacz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kleczynski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Legutko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zmudka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gacon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Przewlocki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kablak-Ziembicka</surname><given-names>A.</given-names></name></person-group><article-title>Expression of mir-1-3p, mir-16-5p and mir-122-5p as possible risk factors of secondary cardiovascular events</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><elocation-id>1055</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines9081055</pub-id><pub-id pub-id-type="pmid">34440258</pub-id><pub-id pub-id-type="pmcid">PMC8391895</pub-id></element-citation></ref><ref id="B24-jcm-12-00946"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Mir-1-3p that correlates with left ventricular function of hcm can serve as a potential target and differentiate hcm from dcm</article-title><source>J. Transl. Med.</source><year>2018</year><volume>16</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1186/s12967-018-1534-3</pub-id><pub-id pub-id-type="pmid">29885652</pub-id><pub-id pub-id-type="pmcid">PMC5994246</pub-id></element-citation></ref><ref id="B25-jcm-12-00946"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.L.</given-names></name></person-group><article-title>Microrna-1 inhibits myocardin-induced contractility of human vascular smooth muscle cells</article-title><source>J. Cell. Physiol.</source><year>2010</year><volume>225</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1002/jcp.22230</pub-id><pub-id pub-id-type="pmid">20458751</pub-id></element-citation></ref><ref id="B26-jcm-12-00946"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sysol</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Comhair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>R.F.</given-names></name></person-group><article-title>Micro-rna-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2018</year><volume>314</volume><fpage>L461</fpage><lpage>L472</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00057.2017</pub-id><pub-id pub-id-type="pmid">29167124</pub-id><pub-id pub-id-type="pmcid">PMC5900352</pub-id></element-citation></ref><ref id="B27-jcm-12-00946"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dakis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brodis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spanos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kouvelos</surname><given-names>G.</given-names></name></person-group><article-title>Circulating biomarkers for the prediction of abdominal aortic aneurysm growth</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>1718</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10081718</pub-id><pub-id pub-id-type="pmid">33923412</pub-id><pub-id pub-id-type="pmcid">PMC8072679</pub-id></element-citation></ref><ref id="B28-jcm-12-00946"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenorio</surname><given-names>E.J.R.</given-names></name><name name-style="western"><surname>Braga</surname><given-names>A.F.F.</given-names></name><name name-style="western"><surname>Tirapelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Piccinato</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Joviliano</surname><given-names>E.E.</given-names></name></person-group><article-title>Expression in whole blood samples of mirna-191 and mirna-455-3p in patients with aaa and their relationship to clinical outcomes after endovascular repair</article-title><source>Ann. Vasc. Surg.</source><year>2018</year><volume>50</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2018.01.086</pub-id><pub-id pub-id-type="pmid">29518510</pub-id></element-citation></ref><ref id="B29-jcm-12-00946"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Major</surname><given-names>M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Eden</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Studzinski</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>O.W.</given-names></name></person-group><article-title>Long-term outcomes and interventions of postoperative type 1a endoleak following elective endovascular aortic aneurysm repair</article-title><source>J. Vasc. Surg.</source><year>2022</year><volume>75</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2021.07.122</pub-id><pub-id pub-id-type="pmid">34324969</pub-id></element-citation></ref><ref id="B30-jcm-12-00946"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karthikesalingam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Vidal-Diez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bahia</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Hinchliffe</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>M.M.</given-names></name></person-group><article-title>The impact of endovascular aneurysm repair on mortality for elective abdominal aortic aneurysm repair in england and the united states</article-title><source>J. Vasc. Surg.</source><year>2016</year><volume>64</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2016.01.057</pub-id><pub-id pub-id-type="pmid">27050198</pub-id></element-citation></ref><ref id="B31-jcm-12-00946"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>P.</given-names></name></person-group><article-title>Single nucleotide polymorphism associated with mature mir-125a alters the processing of pri-mirna</article-title><source>Hum. Mol. Genet.</source><year>2007</year><volume>16</volume><fpage>1124</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm062</pub-id><pub-id pub-id-type="pmid">17400653</pub-id></element-citation></ref><ref id="B32-jcm-12-00946"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroliczewski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sobolewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lejnowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Collawn</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Bartoszewski</surname><given-names>R.</given-names></name></person-group><article-title>Microrna single polynucleotide polymorphism influences on microrna biogenesis and mrna target specificity</article-title><source>Gene</source><year>2018</year><volume>640</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2017.10.021</pub-id><pub-id pub-id-type="pmid">29032146</pub-id></element-citation></ref><ref id="B33-jcm-12-00946"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A genetic variant located in mir-146b promoter region is associated with prognosis of gastric cancer</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2018</year><volume>27</volume><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-17-1054</pub-id><pub-id pub-id-type="pmid">29685895</pub-id></element-citation></ref><ref id="B34-jcm-12-00946"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navickas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Laucevicius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taparauskaite</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zdanyte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holvoet</surname><given-names>P.</given-names></name></person-group><article-title>Identifying circulating micrornas as biomarkers of cardiovascular disease: A systematic review</article-title><source>Cardiovasc. Res.</source><year>2016</year><volume>111</volume><fpage>322</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw174</pub-id><pub-id pub-id-type="pmid">27357636</pub-id><pub-id pub-id-type="pmcid">PMC4996262</pub-id></element-citation></ref><ref id="B35-jcm-12-00946"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Brull</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Sian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenhalgh</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Humphries</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>J.T.</given-names></name></person-group><article-title>Interleukin-6 (il-6) and the prognosis of abdominal aortic aneurysms</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>2260</fpage><lpage>2265</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.103.18.2260</pub-id><pub-id pub-id-type="pmid">11342474</pub-id></element-citation></ref><ref id="B36-jcm-12-00946"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nejim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramirez Castello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Flohr</surname><given-names>T.R.</given-names></name></person-group><article-title>Preoperative leukocytosis among female patients predicts poor postoperative outcomes following endovascular aneurysm repair for intact infrarenal abdominal aortic aneurysms</article-title><source>J. Vasc. Surg.</source><year>2021</year><volume>74</volume><fpage>1843</fpage><lpage>1852.e3</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2021.05.042</pub-id><pub-id pub-id-type="pmid">34174377</pub-id></element-citation></ref><ref id="B37-jcm-12-00946"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnaoutoglou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kouvelos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tzimas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Laou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bouris</surname><given-names>V.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Matsagkas</surname><given-names>M.</given-names></name></person-group><article-title>Relationship between normal preoperative white blood cell count and major adverse events after endovascular repair for abdominal aortic aneurysm: Results of a pilot study</article-title><source>J. Clin. Anesth.</source><year>2017</year><volume>36</volume><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.jclinane.2016.10.032</pub-id><pub-id pub-id-type="pmid">28183566</pub-id></element-citation></ref><ref id="B38-jcm-12-00946"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidersbach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saxby</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carver-Moore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ivey</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>D.</given-names></name></person-group><article-title>Microrna-1 regulates sarcomere formation and suppresses smooth muscle gene expression in the mammalian heart</article-title><source>eLife</source><year>2013</year><volume>2</volume><fpage>e01323</fpage><pub-id pub-id-type="doi">10.7554/eLife.01323</pub-id><pub-id pub-id-type="pmid">24252873</pub-id><pub-id pub-id-type="pmcid">PMC3833424</pub-id></element-citation></ref><ref id="B39-jcm-12-00946"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>F.Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.S.</given-names></name></person-group><article-title>Mir-1-3p and mir-124-3p synergistically damage the intestinal barrier in the aging colon</article-title><source>J. Crohns. Colitis</source><year>2021</year><volume>16</volume><fpage>656</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjab179</pub-id><pub-id pub-id-type="pmcid">PMC9089420</pub-id><pub-id pub-id-type="pmid">34628497</pub-id></element-citation></ref><ref id="B40-jcm-12-00946"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginckels</surname><given-names>P.</given-names></name><name name-style="western"><surname>Holvoet</surname><given-names>P.</given-names></name></person-group><article-title>Oxidative stress and inflammation in cardiovascular diseases and cancer: Role of non-coding rnas</article-title><source>Yale J. Biol. Med.</source><year>2022</year><volume>95</volume><fpage>129</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">35370493</pub-id><pub-id pub-id-type="pmcid">PMC8961704</pub-id></element-citation></ref><ref id="B41-jcm-12-00946"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name></person-group><article-title>A snp of mir-146a is involved in bladder cancer relapse by affecting the function of bladder cancer stem cells via the mir-146a signallings</article-title><source>J. Cell. Mol. Med.</source><year>2020</year><volume>24</volume><fpage>8545</fpage><lpage>8556</lpage><pub-id pub-id-type="doi">10.1111/jcmm.15480</pub-id><pub-id pub-id-type="pmid">32596945</pub-id><pub-id pub-id-type="pmcid">PMC7412697</pub-id></element-citation></ref><ref id="B42-jcm-12-00946"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Genetic variations in micrornas and the risk and survival of renal cell cancer</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>1629</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgu082</pub-id><pub-id pub-id-type="pmid">24681820</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-12-00946-f001" orientation="portrait"><label>Figure 1</label><caption><p>Kaplan&#8211;Meier estimates of the cumulative survival in patients after AAA repair according to SNP rs2155975 (<bold>A</bold>) and rs4591246 (<bold>B</bold>) as well as miR-1-3p expression (<bold>C</bold>). Shaded region indicates 95% confidence interval (CI).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-12-00946-g001.jpg"/></fig><table-wrap position="float" id="jcm-12-00946-t001" orientation="portrait"><object-id pub-id-type="pii">jcm-12-00946-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of the total enrolled population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Alive Group (<italic toggle="yes">n</italic> = 173)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dead Group (<italic toggle="yes">n</italic> = 57)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, years</td><td align="left" valign="middle" rowspan="1" colspan="1">66.36 &#177; 9.84</td><td align="left" valign="middle" rowspan="1" colspan="1">71.75 &#177; 9.13</td><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&lt;65 years, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">68 (39.3%)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (21.1%)</td><td rowspan="2" align="left" valign="middle" colspan="1">
<bold>0.016</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8805;65 years, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">105 (60.7%)</td><td align="left" valign="middle" rowspan="1" colspan="1">45 (78.9%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male sex, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">137 (79.2%)</td><td align="left" valign="middle" rowspan="1" colspan="1">48 (84.2%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.449</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">64 (37.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">25 (43.9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.433</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Drinking, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">34 (19.7%)</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (14.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.431</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">24.06 &#177; 3.62</td><td align="left" valign="middle" rowspan="1" colspan="1">23.40 &#177; 3.51</td><td align="left" valign="middle" rowspan="1" colspan="1">0.239</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Comorbidities</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Coronary artery disease, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">33 (19.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (21.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.847</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Cerebrovascular disease, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">18 (10.4%)</td><td align="left" valign="middle" rowspan="1" colspan="1">10 (17.5%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Peripheral artery disease, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">40 (23.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">16 (28.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.479</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Renal insufficiency, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">17 (9.8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">15 (26.3%)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Atrial fibrillation, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">9 (5.2%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (7.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.741</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Hypertension, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">109 (63.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">42 (73.7%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.151</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Diabetes, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">21 (12.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (21.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.122</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Dyslipidemia, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">106 (61.3%)</td><td align="left" valign="middle" rowspan="1" colspan="1">33 (57.9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.864</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Maximum AAA diameter, cm</td><td align="left" valign="middle" rowspan="1" colspan="1">5.70 &#177; 1.52</td><td align="left" valign="middle" rowspan="1" colspan="1">6.41 &#177; 2.13</td><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>0.010</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&lt;5.0 cm, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">46 (26.6%)</td><td align="left" valign="middle" rowspan="1" colspan="1">10 (17.5%)</td><td rowspan="2" align="left" valign="middle" colspan="1">0.213</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8805;5.0 cm, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">127 (73.4%)</td><td align="left" valign="middle" rowspan="1" colspan="1">47 (82.5%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Presence of surgical complications, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">20 (11.6%)</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (21.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.081</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Presence of postoperative renal dysfunction, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (4.6%)</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (10.5%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.117</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Presence of postoperative respiratory impairment, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (7.5%)</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (12.3%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Presence of reoperation, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">20 (11.6%)</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (14.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.643</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Surgical type</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;EVAR, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">137 (79.2%)</td><td align="left" valign="middle" rowspan="1" colspan="1">49 (86.0%)</td><td rowspan="2" align="left" valign="middle" colspan="1">0.333</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;OAR, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">36 (20.8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (14.0%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cause of death</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Aneurysm-related death, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">/</td><td align="left" valign="middle" rowspan="1" colspan="1">11 (19.3%)</td><td align="left" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Cardiac death, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">/</td><td align="left" valign="middle" rowspan="1" colspan="1">9 (15.8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;Others, n (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (64.9%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values indicate statistically significant <italic toggle="yes">p</italic>-value &lt; 0.05. BMI: body mass index; AAA: abdominal aortic aneurysm; EVAR: endovascular abdominal aortic aneurysm repair; OAR: open aneurysm repair.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-12-00946-t002" orientation="portrait"><object-id pub-id-type="pii">jcm-12-00946-t002_Table 2</object-id><label>Table 2</label><caption><p>Cox regression analysis for the association between studied SNPs and postoperative mortality of AAA patients through 5-year follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">SNP Genotypes</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Alive</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dead</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Multivariate <sup>a</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR (95% CI)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">rs2155975</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 171</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 57</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AA</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AG</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.783 (1.591&#8211;8.997)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.591 (1.489&#8211;8.658)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GG</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4.376 (1.711&#8211;11.191)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.010</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.590 (1.358&#8211;9.487)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AG + GG vs. AA</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.955 (1.697&#8211;9.217)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.668 (1.560&#8211;8.627)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GG vs. AG + AA</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.100</td><td align="center" valign="middle" rowspan="1" colspan="1">1.623 (0.911&#8211;2.893)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.169</td><td align="center" valign="middle" rowspan="1" colspan="1">1.516 (0.838&#8211;2.743)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">rs4591246</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 168</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 55</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GG</td><td align="center" valign="middle" rowspan="1" colspan="1">85</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AG</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.019</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.073 (1.130&#8211;3.804)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.016</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.117 (1.150&#8211;3.898)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AA</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.806 (1.239&#8211;6.355)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.039</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.737 (1.043&#8211;5.400)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AG + AA vs. GG</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.213 (1.236&#8211;3.960)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.225 (1.240&#8211;3.992)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AA vs. AG + GG</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.089</td><td align="center" valign="middle" rowspan="1" colspan="1">1.859 (0.910&#8211;3.800)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.107</td><td align="center" valign="middle" rowspan="1" colspan="1">1.811 (0.880&#8211;3.726)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">rs9989532</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 172</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 57</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TT</td><td align="center" valign="middle" rowspan="1" colspan="1">142</td><td align="center" valign="middle" rowspan="1" colspan="1">47</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TC</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.938</td><td align="center" valign="middle" rowspan="1" colspan="1">1.029 (0.504&#8211;2.099)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.615</td><td align="center" valign="middle" rowspan="1" colspan="1">0.825 (0.390&#8211;1.745)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CC</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.930</td><td align="center" valign="middle" rowspan="1" colspan="1">1.092 (0.151&#8211;7.918)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.962</td><td align="center" valign="middle" rowspan="1" colspan="1">1.051 (0.141&#8211;7.843)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TC + CC vs. TT</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.923</td><td align="center" valign="middle" rowspan="1" colspan="1">1.034 (0.523&#8211;2.047)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.646</td><td align="center" valign="middle" rowspan="1" colspan="1">0.846 (0.416&#8211;1.726)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CC vs. TC + TT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.935</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.086 (0.150&#8211;7.848)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.934</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.088 (0.147&#8211;8.064)</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values indicate statistically significant <italic toggle="yes">p</italic>-value &lt; 0.05. <sup>a</sup>, <italic toggle="yes">p</italic> for association was adjusted by age, renal insufficiency, maximum AAA diameter, presence of surgical complications and presence of postoperative renal dysfunction. AAA: abdominal aortic aneurysm; SNP: single nucleotide polymorphism; HR: hazard ratio; CI: confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-12-00946-t003" orientation="portrait"><object-id pub-id-type="pii">jcm-12-00946-t003_Table 3</object-id><label>Table 3</label><caption><p>Baseline serum miR-1-3p levels between alive and dead patients in the overall and stratified comparisons.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Alive</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dead</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Serum miR-1-3p Expression</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alive </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dead </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Overall</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 111</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">n</italic> = 34</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 &#177; 0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 &#177; 0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.011</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;65 years</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36 &#177; 1.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44 &#177; 0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8805;65 years</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">1.22 &#177; 0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98 &#177; 0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.151</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 &#177; 0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 &#177; 0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 &#177; 0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79 &#177; 0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.168</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AAA size</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;5.0 cm</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43 &#177; 0.97</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 &#177; 0.23</td><td align="center" valign="middle" rowspan="1" colspan="1">0.166</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8805;5.0 cm</td><td align="center" valign="middle" rowspan="1" colspan="1">86</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23 &#177; 0.91</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 &#177; 0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Surgical type</td><td align="center" valign="middle" rowspan="1" colspan="1">EVAR</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 &#177; 0.88</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98 &#177; 0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.120</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">OAR</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 &#177; 1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58 &#177; 0.28</td><td align="center" valign="middle" rowspan="1" colspan="1">0.093</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cause of death</td><td align="center" valign="middle" rowspan="1" colspan="1">Aneurysm-related death</td><td align="center" valign="middle" rowspan="1" colspan="1">111</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 &#177; 0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 &#177; 0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.026</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Cardiac death</td><td align="center" valign="middle" rowspan="1" colspan="1">111</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 &#177; 0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 &#177; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 &#177; 0.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.15 &#177; 0.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.566</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values indicate statistically significant <italic toggle="yes">p</italic>-value &lt; 0.05. AAA: abdominal aortic aneurysm; EVAR: endovascular abdominal aortic aneurysm repair; OAR: open aneurysm repair.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-12-00946-t004" orientation="portrait"><object-id pub-id-type="pii">jcm-12-00946-t004_Table 4</object-id><label>Table 4</label><caption><p>Cox regression analysis for the association between miR-1-3p expression and postoperative mortality of AAA patients through 5-year follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Multivariate <sup>a</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR (95% CI)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">miR-1-3p expression per unit increase</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.024</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.507 (0.281&#8211;0.914)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.030</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.496 (0.264&#8211;0.933)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">miR-1-3p expression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#8195;High levels</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (Ref)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;Low levels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.624 (1.577&#8211;8.324)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.498 (1.478&#8211;8.276)</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values indicate statistically significant <italic toggle="yes">p</italic>-value &lt; 0.05. <sup>a</sup>, <italic toggle="yes">p</italic> for association was adjusted by age, renal insufficiency, maximum AAA diameter, presence of surgical complications and presence of postoperative renal dysfunction. AAA: abdominal aortic aneurysm; HR: hazard ratio; CI: confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-12-00946-t005" orientation="portrait"><object-id pub-id-type="pii">jcm-12-00946-t005_Table 5</object-id><label>Table 5</label><caption><p>Effects of rs2155975 and rs4591246 on the expression of serum miR-1-3p in AAA patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">rs2155975</th><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> Value</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">rs4591246</th><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> Value</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AA</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG + GG </th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GG</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG + AA</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">miR-1-3p expression</td><td align="left" valign="middle" rowspan="1" colspan="1">1.17 &#177; 0.67</td><td align="left" valign="middle" rowspan="1" colspan="1">1.19 &#177; 0.95</td><td align="left" valign="middle" rowspan="1" colspan="1">0.905</td><td align="left" valign="middle" rowspan="1" colspan="1">1.18 &#177; 0.81</td><td align="left" valign="middle" rowspan="1" colspan="1">1.18 &#177; 0.93</td><td align="left" valign="middle" rowspan="1" colspan="1">0.969</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;High levels, n (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">26 (59.1%)</td><td align="left" valign="middle" rowspan="1" colspan="1">39 (38.6%)</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>0.029</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">36 (55.4%)</td><td align="left" valign="middle" rowspan="1" colspan="1">29 (36.3%)</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>0.029</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8195;Low levels, n (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (40.9%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62 (61.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (44.6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 (63.8%)</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values indicate statistically significant <italic toggle="yes">p</italic>-value &lt; 0.05. AAA: abdominal aortic aneurysm.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>